Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q3 2019 · 10-Q
Revenue$102.14M$102.14M−0.8% vs Q3 2018 Net Income$28.86M$28.86M+3.0% vs Q3 2018 EPS Diluted$0.54$0.54+3.8% vs Q3 2018 Operating Income$39,729,000+6.0% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$37,196,000−40.3% Margins · derivedOperating margin38.9%+2.5 pt vs Q3 2018
Net margin28.3%+1.1 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 8, 2019 · 39 d after period end